Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836663 | 0.88 | ALDH1A1 (0.79) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL15836654 | 0.78 | ALDH1A1 (0.98) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL15836650 | 0.78 | ALDH1A1 (0.98) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL31195230 | 0.78 | ALDH1A1 (0.64) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL5432715 | 0.78 | MAPT (1.00) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL10125733 | 0.77 | MAPT (0.70) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL5527258 | 0.77 | MAPT (0.74) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL3300404 | 0.77 | ALDH1A1 (0.84) | ALDH1A1LMNAGAAMAPTMEN1 | |
| SCHEMBL4070839 | 0.76 | ALDH1A1 (0.84) | ALDH1A1LMNAHTTGAAMAPT | |
| SCHEMBL15840800 | 0.75 | KMT2A (1.00) | ALDH1A1LMNAHTTMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885LMNA 2183/4885HTT 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.